Questions before a decision
The strongest question is often not “Can I get it?” It is “What will this way of getting care let a clinician learn about me?”
Compare the shape of care first. Then write down the gaps that still matter.
Compare by what happens
A video visit is not a problem in itself. The warning sign is a check that asks too little: no follow-up questions, no real look at your health, and no chance to ask your own questions.
In-person visit
A clinician can examine the area or symptom that concerns you. This way of getting care can also make local testing and follow-up easier.
The key question stays the same: what human evidence supports KPV for the goal being discussed?
Licensed telehealth
As of September 2026, the clinician needs a license, or some other legal permission, covering the place where you are sitting during the visit.
A video visit has to meet the same bar as a visit in person. If an exam or test is needed, the clinician must arrange it or refer you.
Form-only offer
State-board guidance says a static form alone is not a proper assessment when it cannot gather enough information or allow follow-up questions.
A form whose next questions change with your answers can be part of care. The test is whether a real clinician can ask more and whether you can ask them questions.
Research-labelled item
As of September 2026, a product labelled only for research is not a medicine or a lawful way to get treatment.
A mixing guide, calculator, or similar accessory does not turn it into medical care.
These are sample rules written by the national group of state medical boards. Your own state writes and enforces the rules that actually apply to you.
State medical boards’ model policy for telemedicine State medical boards’ guidance on online prescribing FDA bulk-substance status pageQuestions with leverage
Short questions make vague answers easier to spot.
A clear goal makes it possible to discuss options that already have human evidence.
No human study of KPV had been found as of September 2026. Cell and animal work cannot fill that gap.
“KPV” is a common nickname, not an official medicine name. FDA reviewers found more than one chemical form sold under that one name. That mix-up means a patient could receive a different substance from the one the clinician meant.
Get the name before paying. A state board of pharmacy can confirm whether that pharmacy holds the needed licence.
A batch is one lot of product made at the same time. A purity result shows how much of a sample is the main ingredient; FDA found most KPV test sheets report only that, with no limits on unwanted extras. Ask what other tests were done, and how the lab confirmed the ingredient is really KPV.
The FDA noted that approved care already exists for wounds and for many inflammatory conditions.
Start with the public regulator, not a badge shown on a sales page.
Directory of state medical boards FDA links to state pharmacy licence searches Directory of state boards of pharmacyA blank label is not reassurance
As of September 2026, no KPV product has an FDA-approved label. There is no FDA-reviewed list of drug interactions (problems that can come from taking it with your other medicines), no pregnancy information, and no list of people who must avoid it.
That blank space means the question has not been answered. It does not mean the concern is absent.
Unknown is a real answer
A careful clinician can explain what is not known and how that changes the decision.
Private note sheet
Notes stay in this browser. Nothing is sent to this guide.
Do not place private medical details here if other people use this device.